Newsroom hero banner
split-image
first
Get the latest ZS news and press releases
We apply our knowledge, capabilities and innovation-oriented approach to a broad range of industries and client issues.
true
white
ABOUT ZS
false
Download the report
primary
Second Button CTA Text
secondary
media-first
true
May 26, 2026
grey
ZS named a Leader in 2026 IDC MarketScape for Life Sciences R&D Strategic Consulting
h3
Consulting companies are maturing and innovating to deal with the rapidly evolving clients and industries they serve. See why ZS was named a Leader among top-ranked companies for its innovation, depth and breadth of knowledge and cultural and strategic fit with clients.
true
Read the report
Read the report
primary
arrow-right
image
Join our team
asset
Paste your Ceros HTML code here (do not delete this text, add your code right after it):
Placeholder Logo Alt Text
This is placeholder text for the logo description. Please replace or remove this text when adding a logo.
zs:content-type/press-release,zs:content-type/article,zs:content-type/podcast
Life sciences
Sapio Sciences and ZS partner to advance lab digitalization in biopharma R&D and CMC
2026-06-02T00:00:00.000Z
zs:content-type/press-release
Pharmaceuticals & Biotech
Optimism reigns at J.P. Morgan despite a lack of deals
2026-01-14T00:00:00.000Z
zs:content-type/article
Pharmaceuticals & Biotech
This startup bets AI can get drugs through clinical trials faster
2026-04-17T00:00:00.000Z
zs:content-type/article
Pharmaceuticals & Biotech
The pulse of pharma change in 2026
2026-02-20T00:00:00.000Z
zs:content-type/podcast
Pharmaceuticals & Biotech
What does 2026 hold for biopharma? Part 2: Competitive dynamics
2026-01-19T00:00:00.000Z
zs:content-type/article
Healthcare sector calls for united Federal framework to unlock AI’s full potential
2026-01-15T00:00:00.000Z
zs:content-type/press-release
https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-ai-drug-rd-development/809144/
What’s next for AI and drug R&D
2026-01-09T00:00:00.000Z
zs:content-type/press-release
5 FDA drug approvals to watch in 2026
2026-01-07T00:00:00.000Z
zs:content-type/article
With DTC ads under fire, pharma companies need to pivot
2025-09-22T00:00:00.000Z
zs:content-type/article
Report: How hoteliers can boost profits with noncore assets
2025-09-16T00:00:00.000Z
zs:content-type/article
As Wall Street smells blood in the water, what's ailing consulting and research?
2025-08-19T00:00:00.000Z
zs:content-type/article
Your patient's smartwatch could be a legal timebomb: are you liable?
2025-07-30T00:00:00.000Z
zs:content-type/article
The Myth of All-American Drugs and What Trump’s Tariffs Miss About Pharma Supply Chains
2025-07-23T00:00:00.000Z
zs:content-type/article
COVID vax restrictions may not hamper uptake — but the market is still under pressure
2025-06-10T00:00:00.000Z
zs:content-type/article
The Three Pillars of Pharma’s New Commercial Model
2025-05-12T00:00:00.000Z
zs:content-type/article
The cost of AI in healthcare explained. Is it worth it?
2025-05-01T00:00:00.000Z
zs:content-type/article
Pharmaceuticals & Biotech
Healthcare leaders call for moratorium on state AI laws
2026-01-16T00:00:00.000Z
zs:content-type/article
Pharmaceuticals & Biotech
HLC proposes path to AI regulation, from simple to strenuous
2026-01-15T00:00:00.000Z
zs:content-type/article
Scaling AI’s promise in healthcare: The time is now
2026-04-03T00:00:00.000Z
zs:content-type/podcast
Pharmaceuticals & Biotech
Can rare disease drugmakers trust FDA's promises of flexibility amid string of rejections?
2026-03-02T00:00:00.000Z
zs:content-type/article
Pharmaceuticals & Biotech
TrumpRx debuts with several dozen discounted drugs
2026-02-05T00:00:00.000Z
zs:content-type/article
Travel & Hospitality
How hotels can leverage assets and technology in 2026
2026-01-27T00:00:00.000Z
zs:content-type/podcast
Pharmaceuticals & Biotech
European health chief says EU is at 'a critical point' in ensuring new drug access
2026-04-22T00:00:00.000Z
zs:content-type/article
default
Media contact
For more information, please contact our media relations team.
Contact
Maryam Ayromlou
Ruder Finn
zs-RFMedia@ruderfinn.com
+1 703 474 5685
left
true
grey
MEDIA RESOURCES
Button CTA Text
primary
default
image
ZS’s recognition and rankings
h3
Leading, independent industry experts have recognized ZS’s talent and culture.
Learn more
link
Thank you for requesting a download of the Release Notes. A representative will contact you within 48 hours. If you have any questions, please contact us.
Fact sheet
h3
Get our corporate overview, executive bios and other important information about ZS.
Learn more
link
Thank you for requesting a download of the Release Notes. A representative will contact you within 48 hours. If you have any questions, please contact us.